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Aim of study: Due to increasing life expectancy, patients with breast cancer remain at risk of dying 
due to breast cancer over a long time. This study aims to assess the impact of age on breast cancer 
mortality and other cause mortality ten years after diagnosis.  
Methods: Postmenopausal patients with hormone-receptor positive breast cancer were included in 
the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial between 2001 and 2006. Age at 
diagnosis was categorized as <65 years (n=3369), 65 to 74 years (n=1896) and ≥75 years (n=854). 
Breast cancer mortality was assessed considering other cause mortality as competing event using 
competing risk analysis.  
Results: After a median follow-up of 9.8 years (interquartile range 8.0-10.3), cumulative incidence of 
breast cancer mortality increased with increasing age (age <65 years 11.7% (95% CI 10.2-13.2), 65-74 
years 12.7% (11.2-14.2), ≥ 75 years 15.6% (13.1-18.0). Univariate subdistribution Hazard Ratio (sHR) 
increased with increasing age (age 65-74 years sHR 1.08, 95% confidence interval (CI) 0.92-1.27, ≥75 
years sHR 1.30, 95% CI 1.06-1.58, P= 0.013). Multivariable sHR adjusted for tumour and treatment 
characteristics increased with age but did not reach significance (age 65-74 years sHR 1.11, 95% CI 
0.94-1.31; ≥75 years sHR 1.18, 95% CI 0.94-1.48, P= 0.055).  
Conclusion: Ten years after diagnosis, older age at diagnosis is associated with increasing breast 
cancer mortality in univariate analysis but it did not reach significance in multivariable analysis. This 
is not outweighed by a substantially increasing other cause mortality with older age. This underlines 
the need to improve the balance between undertreatment and overtreatment in older patients with 
breast cancer.   
The trial was registered in international trial databases (ClinicalTrials.gov NCT00279448, 
NCT00032136, and NCT00036270; the Netherlands Trial Registry NTR267). 







 With increasing life expectancy there is a longer period to die due to breast cancer 
 Breast cancer mortality increased with age despite higher competing mortality 
 Even at older age breast cancer remains an important cause of death  
 Older patients are at risk of both undertreatment and overtreatment 





Age is the strongest predictor for the development of breast cancer (1). Due to aging of the 
population, the number of older patients diagnosed with breast cancer is rapidly growing. With 
increasing life expectancy, older patients remain at risk of dying of breast cancer over a longer time 
period. At the same time, the risk of dying from other causes than breast cancer increases 
substantially with advancing age (2). Survival estimates that take these competing causes of death 
into account are essential for individual decision making to balance between benefits and toxicities 
of cancer therapy (3).  
As older patients are poorly represented in clinical trials (4), the relation between age at diagnosis 
and breast cancer mortality was mostly investigated in observational studies, reporting a higher 
breast cancer mortality with increasing age (5-9). Due to lack of information on cause of death, most 
studies use relative survival as a measurement of breast cancer-related survival. The Tamoxifen and 
Exemestane Adjuvant Multicenter (TEAM) trial included a large number of older postmenopausal 
patients, and contains reliable information on cause of death. A previous analysis after five years of 
follow-up observed higher breast cancer mortality with increasing age, despite that increasing age 
was also associated with a higher proportion of other cause mortality (9).  
However, as patients above 75 years currently have an anticipated life expectancy of 12 years and 
breast cancer can recur until 20 years after initial diagnosis (10), it is relevant to investigate how 
breast cancer mortality and other cause mortality compete over a longer time period after breast 
cancer. Therefore, the aim of this study was to assess the relation between age at diagnosis and 
breast cancer mortality and other cause mortality ten years after diagnosis among postmenopausal 




Patients and methods 
The TEAM study is a randomized controlled trial including postmenopausal patients with non-
metastatic estrogen and/or progesterone positive breast cancer. Details of the trial have been 
extensively described in previous publications (11, 12). In short, patients were included between 
2001 and 2006 and randomized to receive exemestane for five years, or tamoxifen followed by 
exemestane for a total duration of five years. If patients had an Eastern Cooperative Oncology Group 
(ECOG) performance status higher than two, a previous malignancy with a disease-free interval of 
fewer than five years or significant cardiac or other diseases interfering with study participation they 
were ineligible. Cause of death was indicated on a case report form and categorized into 10 pre-
specified groups (Table 2). Classification of cause of death was verified centrally by the TEAM 
datacenter. The database was locked on February 19, 2016 for the study endpoints after ten years of 
follow-up. 
For the current analysis, only patients from countries that completed ten years of follow-up were 
included (The Netherlands, Belgium, Luxembourg, United Kingdom, Ireland, Greece and Germany). 
After ten years of follow-up there was no difference in the primary endpoint between the two 
treatment arms (11).  
The trial was registered in international trial databases (ClinicalTrials.gov NCT00279448, 
NCT00032136, and NCT00036270; the Netherlands Trial Registry NTR267; Ethics Commission Trial 
27/2001; and the University hospital Medical Information Network C000000057). Approvals from 
ethical committees and written informed consent from all patients were obtained (12). 
Outcomes 
For age at diagnosis patients were categorized into three categories (<65 years (reference group), 
65-74 years and ≥75 years) according to the guidelines of the International Society of Geriatric 
Oncology (SIOG) (13). Breast cancer mortality was defined as time from randomization to death due 
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to breast cancer. Deaths that occurred after distant recurrence were defined as death due to breast 
cancer with other cause mortality as a competing event. Other cause mortality was defined as all 
other causes of death than breast cancer, and in the analyses breast cancer mortality was 
considered as competing event. Distant recurrence was classified according to the Tumour-Node-
Metastasis classification (6th edition) (14). If patients died due to breast cancer, the presence of 
distant recurrence was assumed and other cause mortality was considered as competing event.  
Statistical Analyses  
Pearson Χ2 test was used to compare proportional differences between age groups. Cumulative 
incidences of breast cancer mortality, other cause mortality and distant recurrence were calculated 
using the Cumulative Incidence Competing Risk Methods (15, 16). The Fine and Gray model was used 
to calculate the effect of prognostic factors for the cause-specific incidences of death or distant 
recurrence taking into account the effect of competing causes of death (16). The effect of prognostic 
factors is expressed as subdistribution hazard ratio’s (sHR) (15, 16). P- values for trend over 
increasing age were reported. The multivariable model included clinically relevant covariates 
(histological grade, tumour size, lymph node status, progesterone receptor status, Her2 receptor 
status, most extensive breast surgery, radiotherapy, chemotherapy, type of endocrine therapy and 
country of residence). Multiple imputation by chained equation was performed to account for 
missing values, assuming that data were missing at random (17). Analyses were based on pooled 
results of five imputed data sets using Rubin’s rules. All statistical tests were two-sided. P-values of 
less than 0.05 were considered statistically significant. All analyses were performed in R version 3.3.0 
using the survival, cmprsk and mice packages.  
Additional analyses 
An additional analysis was performed to assess the impact of age at diagnosis on breast cancer 
mortality in those patients who were diagnosed with a distant recurrence during follow-up. 
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Furthermore, two sensitivity analyses were performed to test the validity of the study endpoints  
(Supplementary Material).   
Results 
Overall, 6119 postmenopausal patients were included. 3369 patients (55%) were aged <65 years, 
1896 were 65-74 years (31%), and 854 patients (14%) were aged ≥75 years at diagnosis. Median 
follow-up was 9.8 years (interquartile range 8.0-10.3). Table 1 shows the baseline characteristics by 
age group. Patients aged ≥75 years were more likely to present with larger tumours, no difference 
was observed in nodal status or differentiation grade. The proportion of patients undergoing a 
mastectomy increased significantly with increasing age, whereas administration of radiotherapy and 
adjuvant chemotherapy decreased significantly with increasing age.  
During follow-up, 551 of 3369 (16%) patients aged <65 years at diagnosis, 467 of 1896 (25%) patients 
aged 65 to 75 years and 443 of 854 (52%) patients aged ≥75 years at diagnosis died. Breast cancer 
was the leading cause of death among all age groups, but proportionally decreased with increasing 
age at diagnosis (Table 2). Ten-year cumulative incidence of breast cancer mortality increased from 
11.7%  in patients aged <65 years, to 12.7%  in patients aged 65-74 years and 15.6% in patients aged 
≥75 years (Table 3, Figure 1). In univariate analysis, increasing age was associated with a higher 
breast cancer mortality (age group 65-74 years sHR 1.08, 95% CI 0.92-1.27; age group ≥75 years sHR 
1.30, 95% CI 1.06-1.58, P= 0.013, Table 3). In multivariable analysis, breast cancer mortality 
increased with advancing age although it did not reach statistical significance (age group 65-74 years 
sHR 1.11, 95% CI 0.94-1.31; age group ≥75 years sHR 1.18, 95% CI 0.94-1.48, P= 0.055, Table 3).  
Ten-year cumulative incidence of other cause mortality increased with older age at diagnosis 
(patients aged <65 years 3.7%; 65-74 years 10.6%; ≥75 years 33.4%, Figure 1). Both models showed a 
strong association between age and other cause mortality (Table 3).  
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Cumulative incidence of distant recurrence increased between five and ten years in all age groups. In 
both models, age was not associated with a higher risk of distant recurrence after ten years (age 
group 65-74 years multivariable sHR 1.05, 95% CI 0.90-1.23, age group ≥75 years 0.97, 95% CI 0.79-
1.20, P= 0.462, Table 3).  
Additional analyses  
Older patients that developed a distant recurrence during follow-up were at higher risk of dying due 
to breast cancer compared to younger patients (patients aged 65-74 years multivariable sHR 1.30, 
95% CI 1.09-1.56; patients aged ≥75 years sHR 2.18, 95% CI 1.70-2.78, P<0.001).  
When not assuming breast cancer as the cause of death after diagnosis of distant recurrence, 39 
deaths originally classified as death due to breast cancer were now considered as death due to other 
causes (Table S1). A similar trend for the effect of age at diagnosis and breast cancer mortality in 
univariate analysis was observed while there was no clear trend between increasing age and breast 
cancer mortality in multivariate analysis (Table S2). Outcomes of further sensitivity analyses are 






After ten years of follow-up, increasing age at diagnosis is associated with higher breast cancer 
mortality and this is not outweighed by a substantially higher other cause mortality. After adjusting 
for breast cancer and treatment characteristics, a similar trend was observed although this did not 
reach significance. Moreover, distant recurrences occurred at a similar rate between younger and 
older patients, despite substantially higher other cause mortality among the oldest patient group. In 
those patients that developed distant recurrence, increasing age was associated with increasing 
breast cancer mortality subsequently. These findings indicate the need to develop prediction tools 
that include both breast cancer and other cause mortality to balance harms and benefits of 
treatment.  
A previous report of the TEAM trial after five years of follow-up described a significant association 
between increasing age and breast cancer mortality, independent of tumour and treatment 
characteristics(9).  In our study cohort, we observed a corresponding trend after adjusting for similar 
confounders but it did not reach significance. There are some possible explanations for the different 
outcomes in both analyses. The population in the current ten-year cohort was different from the 
original population: in the current cohort patients had larger tumours and were more often lymph 
node-positive and a poorer disease-free survival than in the original TEAM population(11). 
Furthermore, the authors applied a Cox model for the main analyses while in this study, a competing 
risk regression model was applied. After the publication of the study in 2012, this study group has 
gained more experience and knowledge in the application and interpretation of the competing risk 
model(3). With this current knowledge it was decided that the competing risk model was more 
appropriate than the Cox model to predict outcomes between age groups. Moreover, in the current 
study multiple imputation analysis was performed to account for missing values.  
In a population with a high probability of competing events it is important to take competing events 
into account when estimating the risk of breast cancer mortality, as it could otherwise overestimate 
the risk of breast cancer mortality(3). Unfortunately, previous studies describing the relation 
11 
 
between age at diagnosis and cause of death among patients diagnosed with breast cancer used 
various statistical techniques. In the ATAC trial, a positive association between increasing age and 
risk of breast cancer recurrence and death without recurrence was reported using the Cox model 
(18). However, this effect of age at diagnosis might be overestimated because competing events 
were not considered (3). In trials from the NCIC Clinical Trials Group, the effect of age at diagnosis on 
breast cancer mortality and competing causes of death was studied using various competing risk 
models (19-21). Age was predictive for breast cancer mortality after 3.9 and 4.1 years of follow-
up(19, 20), but not after 7.9 years of follow-up(21). These findings suggest that there is need for 
consensus on appropriate statistical models to assess the impact of age on breast cancer mortality.  
It is interesting to elaborate why older patients were at higher risk of breast cancer mortality. In this 
study we report similar rates of distant recurrence among all age groups despite substantially higher 
risk of other cause mortality. Older patients had a substantially higher risk to die due to breast 
cancer than younger patients after diagnosis of distant recurrence. This may explain the trend for 
higher breast cancer mortality observed in this study. Unfortunately, there is no further information 
of distant recurrence available and it remains unclear if our results are explained by tumour biology 
or given treatment. In view of our data, we hypothesize that older patients may receive less 
intensive treatment of distant recurrences leading to higher breast cancer mortality. Further 
research hereon is highly warranted.  Moreover, in the multivariable analysis, the trend between age 
and breast cancer mortality did not reach significance, indicating that there is a role for variation in 
tumour or treatment characteristics at baseline. In our study older patients were more likely to 
present with larger tumours than younger patients (Table 1). Previous studies have reported that 
tumour size is directly associated with poorer breast cancer outcomes (22) and that older patients 
are more likely to present with larger tumours (23). Although this might suggest there is a direct 
relationship between tumour size, age and breast cancer mortality, another study has described a 
different relationship between age, tumour size and lymph node involvement among older patients; 
after the age of 70, patients with smaller tumours appeared to have a higher risk of lymph node 
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involvement than patients with larger tumours, suggesting a poorer prognosis for older patients with 
smaller tumours (24).  
Furthermore, older patients were less likely to receive chemotherapy despite having larger tumours 
(Table 1) and this could have influenced the outcomes as well. Previous studies have shown that 
chemotherapy in older patients is as effective as in younger patients, though risk of toxicity is higher 
(13, 25). Due to the very low number of older patients receiving chemotherapy, it was impossible to 
perform further analyses exploring the effect variation of chemotherapy on breast cancer mortality 
and therefore no firm conclusions regarding overtreatment or undertreatment can be derived from 
this data.   
Obviously, other cause mortality is strongly related to age (26). To provide a full overview of the 
prognosis of an individual patient it is of vital importance to investigate factors that are prognostic 
for other cause mortality along with prognostic factors for breast cancer mortality. In patients with 
breast cancer, it has been reported that comorbidities are strongly related to other cause mortality 
(18, 27). Unfortunately, in the TEAM study information on comorbidities was only collected for a 
small subgroup of patients and therefore comorbidities were not included in this analysis. Geriatric 
indicators and comorbidities could be used to predict the risk of toxicities to provide a profound 
estimation of breast cancer mortality, other cause mortality and benefits and harms of treatment 
(28).  
Some additional limitations should be mentioned. First, misclassification of cause of death could 
have occurred and this could possibly influence cause-specific survival outcomes(29). A sensitivity 
analysis was performed applying a less stringent classification of breast cancer mortality. Consistent 
with our main results, a similar trend for increasing breast cancer mortality with increasing age was 
observed. In multivariable analysis, no trend between increasing age at diagnosis and breast cancer 
mortality was observed. This might be explained due to a loss of power as there were fewer breast 
cancer mortality events. Moreover, unknown cause of death was more frequently reported among 
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older patients and this could have influenced our findings. Finally, a previous study has shown that 
older patients included in the TEAM study were relatively healthy compared to the general 
population, which may limit the external validity of the present findings (30).   
In conclusion, this study shows that breast cancer mortality continues to increase after ten years of 
follow-up among postmenopausal patients diagnosed with hormone receptor-positive breast cancer 
regardless of the increasing other cause mortality. In older patients, breast cancer mortality 
remained higher compared to younger patients and this was not outweighed by substantially higher 
other cause mortality. A similar trend was observed in multivariable analysis, although this did not 
reach significance. Moreover, older patients were at a substantially higher risk of dying due to breast 
cancer after diagnosis of distant recurrence. These findings emphasize the impact of breast cancer 
on mortality among older patients and underline the need for prediction tools that include both 
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Table 1. Patient, tumour and treatment characteristics by age at diagnosis 
  < 65 years  65-74 years  ≥ 75 years   
  n=3369  n=1896  n=854   
    n %  %*  n % %*   n % %*  P  
Histological grade               
 G1, well 330 9.8 10.6  200 10.5 11.5  86 10.1 11.6  0.527 
 G2, modeate 1721 51.1 55.5  1011 53.3 56.9  436 51.1 56.2   
 G3, G4, poor 1034 30.7 33.8  553 29.2 31.6  248 29.0 32.2   
 Unknown 284 8.4   132 7.0   84 9.8    
T size              
 T1 1797 53.3 53.5  954 50.3 50.4  275 32.2 32.2  <0.001 
 T2 1353 40.2 40.4  830 43.8 43.9  501 58.7 58.7   
 T3, T4 208 6.2 6.2  107 5.6 5.7  78 9.1 9.1   
 Unknown 11 0.3   5 0.3   0     
N status              
 N0 1437 42.7 42.8  818 43.1 43.4  348 40.7 41.1  0.842 
 N1 1703 50.5 50.7  954 50.3 50.4  442 51.8 52.0   
 N2/N3 221 6.6 6.6  117 6.2 6.2  58 6.8 6.9   
 Unknown  8 0.2   7 0.4   6 0.7    
Progesterone receptor              
 Positive 2431 72.2 72.2  1330 70.1 70.1  616 72.1 72.1  0.275 
 Negative 938 27.8 27.8  1330 29.9 29.9  238 27.9 27.9   
Her2 receptor              
 Positive  328 9.7 13.9  166 8.8 12.4  66 7.7 10.4  0.069 
 Negative  2000 59.4 86.1  1212 63.9 87.6  612 71.7 89.6   
  Unknown  1041 30.9   518 27.3   176 20.6    
Most extensive surgery              
 Mastectomy 1395 41.4 41.5  898 47.4 47.4  580 67.9 68.0  <0.001 
 Wide local excision 1970 58.5 58.5  997 52.6 52.6  273 32.0 32.0   
 Unknown 4 0.1   1 0.1   1 0.1    
Radiotherapy             
 Yes 2499 74.2 74.4  1247 65.8 66.0  420 49.2 49.3  <0.001 
 No 861 25.6 25.6  642 33.9 34.0  431 50.5 50.7   
 Unknown 9 0.3   7 0.4   3 0.4    
Radiotherapy if wide local excision            0.001 
 Yes 1873 95.1 -  922 92.5 -  244 89.4 -   
 No 94 4.8 -  73 7.3 -  28 10.3 -   
 Unknown 3 0.2   2 0.2   1 0.4    
Chemotherapy              
 Yes 1855 55.1 55.1  376 19.8 19.8  21 2.5 2.5  <0.001 
 No  1514 44.9 44.9  1520 80.2 80.2  833 97.5 97.5   
Endocrine therapy              
 Tamoxifen followed by 
exemestane 
1689 50.1 50.1  943 49.7 49.7  413 48.4 48.4  0.651 
 Exemestane  1680 49.9 49.9  953 50.3 50.3  441 51.6 51.6   
Country              
 Germany 871 25.9 25.9  454 23.9 23.9  146 17.1 17.1  <0.001 
 Greece 110 3.3 3.3  71 3.7 3.7  26 3.0 3.0   
 Netherlands and Belgium 1692 50.2 50.2  958 50.5 50.5  516 60.4 60.4   
 United Kingdom and 
Ireland 
696 20.7 20.7  413 21.8 21.8  166 19.4 19.4   
*proportional distribution after multiple imputation 
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Table 2. Cause of death by age at diagnosis 
 < 65 years   65-74 years   ≥ 75 years 
All deaths  n=551 %  n=467 %  n=443 % 
Breast cancer 412 74.8  250 53.5  134 30.2 
Second primary tumour 66 12.0  58 12.4  33 7.4 
Endometrial cancer 1 0.2  2 0.4  0 0 
Cardiac disorder 13 2.4  37 7.9  56 12.6 
Thromboembolism 3 0.5  2 0.4  11 2.5 
Pulmonary disorder 5 0.9  18 3.9  15 3.4 
Cerebral disorder 4 0.7  14 3.0  21 4.7 
Vascular disorder 1 0.2  2 0.4  3 0.7 
Other 21 3.8  50 10.7  111 25.1 
Unknown  21 3.8  34 7.3  59 13.3 




Table 3. Survival outcomes by age at diagnosis 
  Cumulative incidence (%) (95% CI) 
 Univariate sHR
#




   Multivariable sHR
#





  Five years after diagnosis Ten years after diagnosis        
Breast cancer mortality        
 < 65 6.4 (5.6-7.2) 11.7 (10.2-13.2)  Reference 0.013  Reference 0.055 
 65-74 6.6 (5.5-7.7) 12.7 (11.2-14.2)  1.08 (0.92-1.27)   1.11 (0.94-1.31)  
 ≥ 75 8.9 (7.0-10.8) 15.6 (13.1-18.0)  1.30 (1.06-1.58)   1.18 (0.94-1.48)  
Other cause mortality        
 < 65 1.2 (0.7-1.5) 3.7 (3.1-4.3)  Reference <0.001  Reference <0.001 
 65-74 4.9 (3.9-5.9) 10.6 (9.2-12.0)  2.88 (2.33-3.56)   2.44 (1.95-3.06)  
 ≥ 75 14.6 (12.3-17.0) 33.4 (30.2-36.5)  10.53 (8.63-12.86)   7.97 (6.31-10.06)  
Distant recurrence         
 < 65 10.2 (9.2-11.3) 17.8 (16.4-19.2)  Reference 0.462  Reference 0.995 
 65-74 10.0 (8.6-11.3) 18.8 (16.9-20.8)  1.02 (0.89-1.17)   1.05 (0.90-1.23)  
 ≥ 75 12.3 (10.1-14.5) 18.8 (16.0-21.5)  1.07 (0.89-1.29)   0.97 (0.79-1.20)  





Figure 1.  
Title: Cumulative incidence of mortality by cause of death per age group  
Legend: Stacked cumulative incidence of breast cancer mortality (red) and other cause mortality 
(blue) by age group from time since diagnosis.  
 
 
